Company news: Roche

Share this article:
Roche reported disappointing third-quarter sales as key cancer drugs Avastin, Rituxan and Herceptin underperformed. Avastin sales declined 24% in the third quarter, while Herceptin was down 12% and Rituxan sales slid 10%. That, coupled with currency exchange effects, caused the company to miss analyst expectations and trumped an upbeat pipeline report from the firm.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters